Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alaunos Therapeutics, Inc.TCRT · Entity 8339 | CEO | October 06, 2026 | October 08, 2026 |
| JUPITER NEUROSCIENCES, INC.JUNS · Entity 8326 | Director | June 02, 2025 | July 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alaunos Therapeutics, Inc.
Report date October 06, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 49,047 |
Reported balance
After 2026-10-06 transaction · row 1
1 source rowRow 1 · 2026-10-06 · Grant · Acquired 23,564 · Balance 49,047 F1: Represents shares of common stock issued in lieu of net salary. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock issued in lieu of net salary.
JUPITER NEUROSCIENCES, INC.
Report date June 02, 2025 · Filed July 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 96,581 |
Reported balance
After 2025-06-02 transaction · row 1
1 source rowRow 1 · 2025-06-02 · Exercise / conversion · Acquired 85,800 · Balance 96,581 F1: These restricted stock units convert into common stock on a one-for-one basis. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2033-12-17 | Direct | 0 |
Reported balance
After 2025-06-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-02 · Exercise / conversion · Disposed 85,800 · Balance 0 F1: These restricted stock units convert into common stock on a one-for-one basis. F2: Represents restricted stock units which vested on the expiration of the lock-up period for the Issuer's initial public offering. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units convert into common stock on a one-for-one basis.
F2: Represents restricted stock units which vested on the expiration of the lock-up period for the Issuer's initial public offering.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2026 Filed Oct 8, 2026 20:30 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantCommon Stock | 23,564 | $0.74 | $17,541.04 |
DisclosureSEC source: 0001193125-26-417970 · ownership.xml · nonDerivative · entry 1 Weis Holger · CIK 0001846984 · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,047 F1 · shares: Represents shares of common stock issued in lieu of net salary. Read SEC document |
| August 06, 2026 Filed Aug 11, 2026 20:15 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantCommon Stock | 4,363 | $2.01 | $8,769.63 |
DisclosureSEC source: 0001193125-26-344682 · ownership.xml · nonDerivative · entry 1 Weis Holger · CIK 0001846984 · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,483 F1 · shares: Represents shares of common stock issued in lieu of net salary. Read SEC document |
| July 23, 2026 Filed Jul 27, 2026 20:15 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantCommon Stock | 4,568 | $1.92 | $8,770.56 |
DisclosureSEC source: 0001193125-26-318105 · ownership.xml · nonDerivative · entry 1 Weis Holger · CIK 0001846984 · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,120 F1 · shares: Represents shares of common stock issued in lieu of net salary. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 21:33 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantCommon Stock | 3,880 | $2.26 | $8,768.80 |
DisclosureSEC source: 0001193125-26-295004 · ownership.xml · nonDerivative · entry 1 Weis Holger · CIK 0001846984 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,552 F1 · shares: Represents shares of common stock issued in lieu of net salary. Read SEC document |
| June 12, 2026 Filed Jun 17, 2026 20:47 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantCommon Stock | 7,761 | $2.26 | $17,539.86 |
DisclosureSEC source: 0001193125-26-274305 · ownership.xml · nonDerivative · entry 1 Weis Holger · CIK 0001846984 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,672 F1 · shares: Represents shares of common stock issued in lieu of net salary. Read SEC document |
| June 02, 2026 Filed Jun 5, 2026 00:47 UTC | JUPITER NEUROSCIENCES, INC. JUNS · Entity 8326 | GrantStock Option · Derivative | 100,000 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0001493152-26-027354 · ownership.xml · derivative · entry 1 Weis Holger · CIK 0001846984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2036-06-02 F1 · derivative.exercise_date: The options were granted under the Issuer's 2025 Equity Incentive Plan. The options vest over three years commencing from September 2, 2026 in equal quarterly installments subject to continued service through each vesting date. Read SEC document |
| May 22, 2026 Filed May 27, 2026 20:33 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantCommon Stock | 3,700 | $2.37 | $8,769.00 |
DisclosureSEC source: 0001193125-26-241999 · ownership.xml · nonDerivative · entry 1 Weis Holger · CIK 0001846984 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,911 F1 · shares: Represents shares of common stock issued in lieu of net salary. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 23:53 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 13,676 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0000950170-25-110530 · ownership.xml · derivative · entry 1 Weis Holger · CIK 0001846984 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,676 Underlying: Common Stock · 13,676 shares Expires 2035-08-17 F1 · derivative.exercise_date: These options are fully vested as of August 18, 2025. Read SEC document |
| July 02, 2025 Filed Jul 7, 2025 23:08 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 130,000 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0000950170-25-094383 · ownership.xml · derivative · entry 1 Weis Holger · CIK 0001846984 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2035-07-01 F1 · derivative.exercise_date: 25% of this grant will vest and become exercisable immediately upon grant and the remaining balance shall vest in substantially equal quarterly installments over a three year period commencing on the Start Date with the first vesting date being October 2, 2025, subject to holder's continuous employment through each vesting date. This option grant shall be subject to the terms and conditions of the Company's 2020 Equity Incentive Plan and a Stock Option Agreement. Read SEC document |
| June 02, 2025 Filed Jul 13, 2026 20:00 UTC | JUPITER NEUROSCIENCES, INC. JUNS · Entity 8326 | Exercise / conversionRestricted Stock Units · Derivative | 85,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-033013 · ownership.xml · derivative · entry 2 Weis Holger · CIK 0001846984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 85,800 shares Expires 2033-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: Represents restricted stock units which vested on the expiration of the lock-up period for the Issuer's initial public offering. Read SEC document |
| June 02, 2025 Filed Jul 13, 2026 20:00 UTC | JUPITER NEUROSCIENCES, INC. JUNS · Entity 8326 | Exercise / conversionCommon Stock | 85,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-26-033013 · ownership.xml · nonDerivative · entry 1 Weis Holger · CIK 0001846984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,581 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| April 13, 2025 Filed Apr 16, 2025 00:33 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 10,904 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0000950170-25-054432 · ownership.xml · derivative · entry 1 Weis Holger · CIK 0001846984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,904 Underlying: Common Stock · 10,904 shares Expires 2035-04-12 F1 · derivative.exercise_date: These options are fully vested as of April 13, 2025. Read SEC document |
| January 22, 2025 Filed Jan 24, 2025 19:33 UTC | JUPITER NEUROSCIENCES, INC. JUNS · Entity 8326 | Exercise / conversionConvertible Notes · Derivative | 10,781 | $2.80 Strike: $2.80 | $30,186.80 |
DisclosureSEC source: 0001493152-25-003549 · ownership.xml · derivative · entry 2 Weis Holger · CIK 0001846984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,781 Underlying: Common Stock · 10,781 shares Expires 2024-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock issued upon the conversion of that certain Convertible Promissory Note, dated as of September 15, 2021 with a principal balance of $25,000 and conversion price of $2.80 per share. Subject to lock-up obligations for 180 days following the closing of the Issuer's initial public offering, as per Lock-Up Agreement, dated as of November 27, 2024, with Dominari Securities LLC. F1 · derivative.underlying_shares: Shares of common stock issued upon the conversion of that certain Convertible Promissory Note, dated as of September 15, 2021 with a principal balance of $25,000 and conversion price of $2.80 per share. Subject to lock-up obligations for 180 days following the closing of the Issuer's initial public offering, as per Lock-Up Agreement, dated as of November 27, 2024, with Dominari Securities LLC. Read SEC document |
| January 22, 2025 Filed Jan 24, 2025 19:33 UTC | JUPITER NEUROSCIENCES, INC. JUNS · Entity 8326 | Exercise / conversionCommon Stock, par value $0.0001 per share | 10,781 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-25-003549 · ownership.xml · nonDerivative · entry 1 Weis Holger · CIK 0001846984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of common stock issued upon the conversion of that certain Convertible Promissory Note, dated as of September 15, 2021 with a principal balance of $25,000 and conversion price of $2.80 per share. Subject to lock-up obligations for 180 days following the closing of the Issuer's initial public offering, as per Lock-Up Agreement, dated as of November 27, 2024, with Dominari Securities LLC. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 21:00 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 4,524 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0000950170-24-071401 · ownership.xml · derivative · entry 2 Weis Holger · CIK 0001846984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,524 Underlying: Common Stock · 4,524 shares Expires 2034-06-05 F2 · derivative.exercise_date: These options are fully vested as of June 6, 2024. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 21:00 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 19,200 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0000950170-24-071401 · ownership.xml · derivative · entry 1 Weis Holger · CIK 0001846984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,200 Underlying: Common Stock · 19,200 shares Expires 2034-06-05 F1 · derivative.exercise_date: One-twelfth of the Option vests each month on the monthly anniversary of June 6, 2024, with any amount that remains unvested on the date immediately preceding the Company's 2025 annual general meeting of stockholders vesting thereon. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 21:10 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0000899243-23-014910 · doc4.xml · derivative · entry 1 Weis Holger · CIK 0001846984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-06-05 F1 · derivative.exercise_date: One-twelfth of the shares underlying the option vest in equal monthly installments measured from June 6, 2023, with the first vesting occurring on July 6, 2023, subject to the Reporting Person's continued service through each such date. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 20:30 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0000899243-22-023977 · doc4.xml · derivative · entry 6 Weis Holger · CIK 0001846984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-06-21 F2 · derivative.exercise_date: The option vests in twelve equal monthly installments beginning on July 13, 2022. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 20:30 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-023977 · doc4.xml · nonDerivative · entry 1 Weis Holger · CIK 0001846984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,167 F1 · balance_after: Includes 30,000 shares held in a joint account by the Reporting Person and his spouse. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:23 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | PurchaseCommon Stock | 50,000 | $1.83 | $91,500.00 |
DisclosureSEC source: 0001209191-21-054828 · doc4.xml · nonDerivative · entry 1 Weis Holger · CIK 0001846984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,167 F1 · balance_after: Includes 30,000 shares held in a joint account by the Reporting Person and his spouse. Read SEC document |
| March 04, 2021 Filed May 6, 2021 23:27 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-030746 · doc4.xml · derivative · entry 7 Weis Holger · CIK 0001846984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-03-03 F4 · derivative.exercise_date: 1/36th of the shares underlying this option will vest in equal monthly installments commencing one month after 12/15/2020. Read SEC document |
| March 04, 2021 Filed May 6, 2021 23:27 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantStock Option (right to buy) · Derivative | 31,250 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-030746 · doc4.xml · derivative · entry 6 Weis Holger · CIK 0001846984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,250 Underlying: Common Stock · 31,250 shares Expires 2031-03-03 F3 · derivative.exercise_date: 1/3rd of the shares underlying this option will vest on 4/4/2021, 5/4/2021 and 5/19/2021. Read SEC document |
| March 04, 2021 Filed May 6, 2021 23:27 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantCommon Stock | 4,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-030746 · doc4.xml · nonDerivative · entry 1 Weis Holger · CIK 0001846984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,167 F1 · shares: The shares will vest on 5/19/2021. F2 · balance_after: Includes 30,000 shares held in a joint account by the Reporting Person and his spouse. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.